Insider Selling: Nektar Therapeutics (NKTR) CAO Sells 1,928 Shares of Stock

Share on StockTwits

Nektar Therapeutics (NASDAQ:NKTR) CAO Jillian B. Thomsen sold 1,928 shares of Nektar Therapeutics stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $31.37, for a total transaction of $60,481.36. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Jillian B. Thomsen also recently made the following trade(s):

  • On Tuesday, February 19th, Jillian B. Thomsen sold 1,808 shares of Nektar Therapeutics stock. The stock was sold at an average price of $42.39, for a total transaction of $76,641.12.

Shares of NKTR traded up $0.68 during mid-day trading on Friday, reaching $32.02. The company’s stock had a trading volume of 1,480,671 shares, compared to its average volume of 1,752,666. The company has a debt-to-equity ratio of 0.21, a quick ratio of 14.83 and a current ratio of 14.94. Nektar Therapeutics has a 52 week low of $29.22 and a 52 week high of $92.17. The firm has a market cap of $5.91 billion, a price-to-earnings ratio of 8.47 and a beta of 2.96.

Nektar Therapeutics (NASDAQ:NKTR) last issued its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.03. Nektar Therapeutics had a net margin of 55.65% and a return on equity of 37.63%. The company had revenue of $28.22 million for the quarter, compared to the consensus estimate of $25.45 million. During the same period in the previous year, the firm earned ($0.60) earnings per share. As a group, equities research analysts predict that Nektar Therapeutics will post -3.14 earnings per share for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Horizon Investments LLC increased its stake in shares of Nektar Therapeutics by 66.5% in the first quarter. Horizon Investments LLC now owns 10,122 shares of the biopharmaceutical company’s stock worth $340,000 after buying an additional 4,043 shares during the period. BlueMountain Capital Management LLC increased its stake in shares of Nektar Therapeutics by 789.3% in the first quarter. BlueMountain Capital Management LLC now owns 310,528 shares of the biopharmaceutical company’s stock worth $10,434,000 after buying an additional 275,609 shares during the period. Ladenburg Thalmann Financial Services Inc. increased its stake in shares of Nektar Therapeutics by 15.0% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 20,580 shares of the biopharmaceutical company’s stock worth $692,000 after buying an additional 2,685 shares during the period. Metropolitan Life Insurance Co NY increased its stake in shares of Nektar Therapeutics by 14.1% in the first quarter. Metropolitan Life Insurance Co NY now owns 37,534 shares of the biopharmaceutical company’s stock worth $757,000 after buying an additional 4,624 shares during the period. Finally, Utah Retirement Systems increased its stake in shares of Nektar Therapeutics by 5.5% in the first quarter. Utah Retirement Systems now owns 30,692 shares of the biopharmaceutical company’s stock worth $1,031,000 after buying an additional 1,592 shares during the period. 94.90% of the stock is currently owned by institutional investors.

NKTR has been the subject of a number of recent research reports. BidaskClub lowered shares of Nektar Therapeutics from a “sell” rating to a “strong sell” rating in a report on Thursday, April 18th. Piper Jaffray Companies set a $100.00 price objective on shares of Nektar Therapeutics and gave the stock a “buy” rating in a report on Friday, March 1st. Mizuho restated a “buy” rating and issued a $81.00 price objective on shares of Nektar Therapeutics in a report on Wednesday, January 23rd. ValuEngine upgraded shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, May 1st. Finally, Leerink Swann initiated coverage on shares of Nektar Therapeutics in a report on Friday, March 15th. They issued a “market perform” rating for the company. One analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $69.73.

WARNING: This story was first posted by Macon Daily and is the sole property of of Macon Daily. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://macondaily.com/2019/05/17/insider-selling-nektar-therapeutics-nktr-cao-sells-1928-shares-of-stock.html.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.

Featured Article: How to Profit and Limit Losses With Stop Orders

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.